These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 28793993)
1. Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomized, placebo-controlled trial. Tribler S; Brandt CF; Petersen AH; Petersen JH; Fuglsang KA; Staun M; Broebech P; Moser CE; Jeppesen PB Am J Clin Nutr; 2017 Sep; 106(3):839-848. PubMed ID: 28793993 [No Abstract] [Full Text] [Related]
2. A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients. Gudiol C; Arnan M; Aguilar-Guisado M; Royo-Cebrecos C; Sánchez-Ortega I; Montero I; Martín-Gandul C; Laporte-Amargós J; Albasanz-Puig A; Nicolae S; Perayre M; Berbel D; Tebe C; Riera J; Sureda A; Cisneros JM; Carratalà J Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712211 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of taurolidine-citrate in a cohort of patients with intestinal failure receiving home parenteral nutrition. Williams TJ; Moy N; Kaazan P; Callaghan G; Holtmann G; Martin N JPEN J Parenter Enteral Nutr; 2024 Feb; 48(2):165-173. PubMed ID: 38062902 [TBL] [Abstract][Full Text] [Related]
4. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT). Gudiol C; Nicolae S; Royo-Cebrecos C; Aguilar-Guisado M; Montero I; Martín-Gandul C; Perayre M; Berbel D; Encuentra M; Arnan M; Cisneros-Herreros JM; Carratalà J Trials; 2018 May; 19(1):264. PubMed ID: 29720244 [TBL] [Abstract][Full Text] [Related]
5. Taurolidine lock in home parenteral nutrition in adults: results from an open-label randomized controlled clinical trial. Klek S; Szczepanek K; Hermanowicz A; Galas A JPEN J Parenter Enteral Nutr; 2015 Mar; 39(3):331-5. PubMed ID: 24604029 [TBL] [Abstract][Full Text] [Related]
6. Strategies to Reduce Catheter-Related Bloodstream Infections in Pediatric Patients Receiving Home Parenteral Nutrition: The Efficacy of Taurolidine-Citrate Prophylactic-Locking. Lambe C; Poisson C; Talbotec C; Goulet O JPEN J Parenter Enteral Nutr; 2018 Aug; 42(6):1017-1025. PubMed ID: 29385236 [TBL] [Abstract][Full Text] [Related]
7. A 2% taurolidine catheter lock solution prevents catheter-related bloodstream infection (CRBSI) and catheter dysfunction in hemodialysis patients. Neusser MA; Bobe I; Hammermeister A; Wittmann U Br J Nurs; 2021 Jul; 30(14):S24-S32. PubMed ID: 34288746 [TBL] [Abstract][Full Text] [Related]
8. Taurolidine and Heparin as Catheter Lock Solution for Central Venous Catheters in Hemodialysis. Nguyen T; Camins BC; Butler DA Am J Ther; 2024 Jul-Aug 01; 31(4):e398-e409. PubMed ID: 38710029 [TBL] [Abstract][Full Text] [Related]
9. Catheter salvage or removal in catheter-related bloodstream infections with Staphylococcus aureus in children with chronic intestinal failure receiving home parenteral nutrition and the use of prophylactic taurolidine catheter lock solution: A descriptive cohort study. Demirok A; Illy DHC; Nagelkerke SQ; Lagerweij MF; Benninga MA; Tabbers MM JPEN J Parenter Enteral Nutr; 2024 May; 48(4):486-494. PubMed ID: 38605559 [TBL] [Abstract][Full Text] [Related]
10. Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition. Wouters Y; Theilla M; Singer P; Tribler S; Jeppesen PB; Pironi L; Vinter-Jensen L; Rasmussen HH; Rahman F; Wanten GJA Aliment Pharmacol Ther; 2018 Aug; 48(4):410-422. PubMed ID: 29978597 [TBL] [Abstract][Full Text] [Related]
14. Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock. Chu HP; Brind J; Tomar R; Hill S J Pediatr Gastroenterol Nutr; 2012 Oct; 55(4):403-7. PubMed ID: 22595973 [TBL] [Abstract][Full Text] [Related]
15. Use of Catheter Lock Solutions in Patients Receiving Home Parenteral Nutrition: A Systematic Review and Individual-Patient Data Meta-Analysis. Wouters Y; Causevic E; Klek S; Groenewoud H; Wanten GJA JPEN J Parenter Enteral Nutr; 2020 Sep; 44(7):1198-1209. PubMed ID: 31985068 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of taurolidine on the prevention of catheter-related bloodstream infections in patients on home parenteral nutrition. Al-Amin AH; Sarveswaran J; Wood JM; Burke DA; Donnellan CF J Vasc Access; 2013; 14(4):379-82. PubMed ID: 23817948 [TBL] [Abstract][Full Text] [Related]
17. Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin. Handrup MM; Møller JK; Schrøder H Pediatr Blood Cancer; 2013 Aug; 60(8):1292-8. PubMed ID: 23417891 [TBL] [Abstract][Full Text] [Related]
18. Clinical and economic impact of the taurolidine lock on home parenteral nutrition. Arnoriaga Rodríguez M; Pérez de Ciriza Cordeu M; Camblor Álvarez M; Bretón Lesmes I; Motilla de la Cámara M; Velasco Gimeno C; Arhip L; García Peris P; Cuerda Compés C Nutr Hosp; 2018 Jun; 35(4):761-766. PubMed ID: 30070861 [TBL] [Abstract][Full Text] [Related]
19. Taurolidine lock is superior to heparin lock in the prevention of catheter related bloodstream infections and occlusions. Olthof ED; Versleijen MW; Huisman-de Waal G; Feuth T; Kievit W; Wanten GJ PLoS One; 2014; 9(11):e111216. PubMed ID: 25379781 [TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of the efficacy of taurolidine in reducing catheter-related bloodstream infections for patients receiving parenteral nutrition. Vernon-Roberts A; Lopez RN; Frampton CM; Day AS JPEN J Parenter Enteral Nutr; 2022 Sep; 46(7):1535-1552. PubMed ID: 35233792 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]